(Q39788711)

14 September 2017

1 reference

title

Pharmacology of Ergot Alkaloids in Clinical Use (English)

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

10 April 2023

0 references

1 reference

B. Berde

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A370528

10 April 2023

language of work or name

English

0 references

publication date

1 November 1978

1 reference

14 September 2017

4 November 1978

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=370528

full work available at URL

10 April 2023

number of pages

11

1 reference

based on heuristic

inferred from page(s)

https://onlinelibrary.wiley.com/doi/pdf/10.5694/j.1326-5377.1978.tb77379.x

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Medical Journal of Australia

10 April 2023

published in

1 reference

14 September 2017

volume

2

1 reference

14 September 2017

issue

3 Suppl

1 reference

14 September 2017

page(s)

3-13

1 reference

THE ACTION OF ERGOT PREPARATIONS ON THE PUERPERAL UTERUS: A CLINICAL INVESTIGATION WITH SPECIAL REFERENCE TO AN ACTIVE CONSTITUENT OF ERGOT AS YET UNIDENTIFIED

14 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Responsiveness of isolated canine cerebral and peripheral arteries to ergotamine.

10 April 2023

2

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Regional differences in the responsiveness of isolated arteries from cattle, dog and man

10 April 2023

3

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Investigations on the mode of action of ergotamine in the isolated femoral vein of the dog.

10 April 2023

5

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Human plasma levels of some anti-migraine drugs

10 April 2023

7

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

THE SUBSTANCE RESPONSIBLE FOR THE TRADITIONAL CLINICAL EFFECT OF ERGOT

10 April 2023

10

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

10 April 2023

THE NEW ERGOT ALKALOID

12

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

A study of the adrenotropic receptors

10 April 2023

15

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Uterine response to nerve stimulation; relation to hormonal status and catecholamines

10 April 2023

22

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Adrenergic receptors in the myometrium

10 April 2023

23

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Blockade of the biochemical correlates of contraction and relaxation in uterine and intestinal smooth muscle

10 April 2023

24

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Oxytocic and toxic actions of dihydroergotamine-45

10 April 2023

27

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

A study of the effects of dihydroergotamine on the intact human uterus. II. Oxytocic properties

10 April 2023

28

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

The animal pharmacology of drugs used in the treatment of migraine

10 April 2023

32

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Studies of the effect of natural and synthetic polypeptide type ergot compounds on a peripheral vascular bed.

10 April 2023

38

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine--studies in an experimental model for migraine

10 April 2023

40

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Effect of caffeine on intestinal absorption of ergotamine in man.

10 April 2023

42

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Studies in headache; summary of evidence concerning a noxious agent active locally during migraine headache

10 April 2023

46

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Prophylactic and therapeutic properties of 1-methyl-lysergic acid butanolamide in migraine

10 April 2023

47

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

The effects of antimigraine drugs on the vascular responses by-5-hydroxytryptamine and related biogenic substances on the external carotid bed of dogs: possible pharmacological implications to their antimigraine action

10 April 2023

50

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Selective vasoconstriction in carotid vascular bed by methysergide: possible relevance to its antimigraine effect.

10 April 2023

51

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Responsiveness of isolated cerebral and peripheral arteries to serotonin, norepinephrine, and transmural electrical stimulation.

10 April 2023

53

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Drugs which antagonize 5-hydroxytryptamine

10 April 2023

56

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Comparative Effects of Dihydroergotamine and Noradrenaline on Resistance, Exchange and Capacitance Functions in the Peripheral Circulation

10 April 2023

59

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total-hip replacement

10 April 2023

61

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Effect of Dihydroergotoxine on Cyclic-AMP-Generating Systems in Rat Cerebral Cortex Slices

10 April 2023

64

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

The actions of Hydergine on the brain. A histochemical, circulatory and neurophysiological study.

10 April 2023

66

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

The effect of dihydroergotoxin, phentolamine and pindolol on catecholamine-stimulated adenylcyclase in rat cerebral cortex

10 April 2023

71

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

An Ergot Alkaloid Preparation (Hydergine) in Geriatric Therapy

10 April 2023

72

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

An Ergot Alkaloid Preparation (Hydergine) Versus Placebo for Treatment of Symptoms of Cerebrovascular Insufficiency: Double-Blind Study

10 April 2023

76

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

An Ergot Alkaloid Preparation (Hydergine) versus Papaverine in Treating Common Complaints of the Aged: Double-Blind Study

10 April 2023

77

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

A double-blind evaluation of 'Hydergine' and placebo in the treatment of patients with organic brain syndrome and cerebral arteriosclerosis in a nursing home

10 April 2023

78

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Pharmacotherapy for organic brain syndrome in late life. Evaluation of an ergot derivative vs placebo

10 April 2023

79

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Long-term treatment of cerebrovascular changes in the elderly (author's transl)

10 April 2023

80

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Ergotoxine inhibition of deciduoma formation and its reversal by progesterone

10 April 2023

81

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Disturbance of hormone balance in the female rat by a single injection of ergotoxine ethanesulphonate

10 April 2023

82

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Experimental studies on the effect of ergocornine methanesulphonate on the luteotrophic function of the rat pituitary gland.

10 April 2023

83

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

[2-Br-alpha-ergokryptin: influence on fertility and lactation in the rat]

10 April 2023

84

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Effects of ergocornine and 2-Br-α-ergokryptin (CB-154) on the formation of mammary hyperplastic alveolar nodules and the pituitary prolactin levels in mice

10 April 2023

85

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Electrophoretic evidence for human prolactin

10 April 2023

87

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Treatment of Non-puerperal Galactorrhoea with an Ergot Alkaloid

10 April 2023

88

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Galactorrhoea: Successful Treatment with Reduction of Plasma Prolactin Levels by Brom-ergocryptine

10 April 2023

90

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration

10 April 2023

91

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Bromocriptine in Parkinsonism.

10 April 2023

92

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Bromocriptine treatment of acromegaly

10 April 2023

93

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Effects of CB-154 (2-Br-α-Ergocryptine) on Prolactin and Growth Hormone Release in an Acromegalic Patient with Galactorrhea

10 April 2023

94

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Antagonism of 2-Br-α-ergokryptine-methanesulfonate (CB 154) to certain endocrine actions of centrally active drugs

10 April 2023

96

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Adenohypophysis:prolactin

10 April 2023

100

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Studies on the Mechanism of the Dopamine-Mediated Inhibition of Prolactin Secretion1

10 April 2023

104

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Receptor activity and turnover of dopamine and noradrenaline after neuroleptics

10 April 2023

105

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

The role of catecholamines in the release of anterior pituitary prolactin in vitro

10 April 2023

106

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Neuropharmacological Aspects of the Neural Control of Prolactin Secretion

10 April 2023

108

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Changes in Plasma Growth Hormone Levels in Normal and Acromegalic Subjects Following Administration of 2-Bromo-α-Ergocryptine

10 April 2023

111

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Inhibitory effect of an ergoline derivative, methergoline, on growth hormone and prolactin levels in acromegalic patients

10 April 2023

113

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Effects of 2-bromo-alpha-ergocryptine and pimozide on growth hormone secretion in man

10 April 2023

114

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Dopamine and inhibition of prolactin and growth-hormone secretion

10 April 2023

115

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Effect of dopamine infusion on plasma levels of growth hormone in normal subjects and in agromegalic patients

10 April 2023

116

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Letter: Dopamine-induced inhibition of prolactin and growth hormone secretion in acromegaly

10 April 2023

118

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Bromocriptine inhibits prolactin and growth-hormone release by human pituitary tumours in culture

10 April 2023

119

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Blockade of Ovulation in the Immature Rat by Local Microinjection of α-Methyl-Dopa into the Arcuate Region of the Hypothalamus

10 April 2023

120

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Tubero-infundibular dopamine neurons and the secretion of luteinizing hormone and prolactin: extrahypothalamic influences, interaction with cholinergic systems and the effect of urethane anesthesia

10 April 2023

121

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Lack of action of prolactin suppression on the regulation of the human menstrual cycle

10 April 2023

123

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

The Inhibitory Effect of Dopamine Agonists on LH Release in Women1

10 April 2023

124

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Effects of dopamine infusion on pituitary hormone secretion in humans

10 April 2023

125

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Effect of administration of sulpiride on serum follicle-stimulating hormone and luteinizing hormone levels in a group of postmenopausal women

10 April 2023

129

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Correlation of behavioural inhibition or excitation produced by bromocriptine with changes in brain catecholamine turnover

10 April 2023

133

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Apomorphine as an antagonist of the dopamine response from the nucleus accumbens

10 April 2023

136

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.

10 April 2023

137

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Bromocriptin and methylergometrine : Pharmacological approach of the mechanism of their central effects

10 April 2023

138

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system.

10 April 2023

142

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons.

10 April 2023

143

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

INFLUENCE OF THE SUBSTANTIA NIGRA ON THE CATECHOLAMINE CONTENT OF THE STRIATUM

10 April 2023

146

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

The effects of centrally acting drugs on tremor in monkeys with mesencephalic lesions

10 April 2023

147

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Tremor and Involuntary Movements in Monkeys: Effect of L-Dopa and of a Dopamine Receptor Stimulating Agent

10 April 2023

148

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Long-lasting anti-tremor induced by 2-Br-alpha-ergocryptine in monkeys

10 April 2023

149

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Effect of ergot drugs on central 5-hydroxytryptamine neurons: evidence for 5-hydroxytryptamine release or 5-hydroxytryptamine receptor stimulation

10 April 2023

151

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Neurochemical and Neuropharmacological Investigations with Four Ergot Derivatives: Bromocriptine, Dihydroergotoxine, CF 25-397 and CM 29-712

10 April 2023

152

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

10 April 2023

Molecular Pharmacology

153

12

800

Burt D. R.

1976

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Dopamine receptors in human and calf brains, using [3H]apomorphine and an antipsychotic drug

10 April 2023

154

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor".

10 April 2023

161

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Dopamine Receptors in the Brain

10 April 2023

162

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Subcellular localization of dopamine-sensitive adenylate cyclase in rat brain striatum

10 April 2023

163

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Effects of bromocriptine on central dopaminergic receptors

10 April 2023

164

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Direct evidence for the stimulation of rabbit retina dopamine receptors by ergot alkaloids

10 April 2023

165

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Interaction of ergot drugs with central monoamine systems. Evidence for a high potential in the treatment of mental and neurological disorders

10 April 2023

166

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Letter: Bromocriptine and hypertension

10 April 2023

168

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

Hyperprolactinaemia and antihypertensive effect of bromocriptine in essential hypertension. Identification of abnormal central dopamine control

10 April 2023

169

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1978.TB77379.X

10 April 2023

Identifiers

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=370528

10 April 2023

1 reference